CRIS Curis Inc

Price (delayed)

$8.26

Market cap

$756.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$686.91M

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of ...

Highlights

Curis's EPS has surged by 52% YoY and by 10% QoQ

CRIS's debt is down by 34% YoY and by 16% from the previous quarter

The net income is down by 14% since the previous quarter and by 9% year-on-year

CRIS's quick ratio is down by 13% since the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.curis.com

Peers: EXEL INFI EBS SPPI

Key stats

What are the main financial stats of CRIS

Market

Shares outstanding

91.6M

Market cap

$756.59M

Enterprise value

$686.91M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

6.72

Price to sales (P/S)

73.84

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

67.07

Earnings

Revenue

$10.24M

EBIT

-$34.26M

EBITDA

-$33.54M

Free cash flow

-$31.61M

Per share

EPS

-$0.43

Free cash flow per share

-$0.35

Book value per share

$1.23

Revenue per share

$0.11

TBVPS

$1.88

Balance sheet

Total assets

$181.19M

Total liabilities

$68.72M

Debt

$5.35M

Equity

$112.47M

Working capital

$148.67M

Liquidity

Debt to equity

0.05

Current ratio

19.9

Quick ratio

19.7

Net debt/EBITDA

2.08

Margins

EBITDA margin

-327.5%

Gross margin

95%

Net margin

-334.5%

Operating margin

-297.2%

Efficiency

Return on assets

-22%

Return on equity

-40.7%

Return on invested capital

-57.1%

Return on capital employed

-19.8%

Return on sales

-334.5%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

CRIS stock price

How has the Curis stock price performed over time

Intraday

-2.02%

1 week

1.72%

1 month

-1.2%

1 year

671.96%

YTD

0.85%

QTD

2.35%

Financial performance

How have Curis's revenue and profit performed over time

Revenue

$10.24M

Gross profit

$9.73M

Operating income

-$30.44M

Net income

-$34.26M

Gross margin

95%

Net margin

-334.5%

CRIS's operating margin is down by 25% year-on-year and by 22% since the previous quarter

Curis's operating income has decreased by 21% QoQ and by 15% YoY

CRIS's net margin is down by 19% YoY and by 15% from the previous quarter

The net income is down by 14% since the previous quarter and by 9% year-on-year

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation

P/E

N/A

P/B

6.72

P/S

73.84

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

67.07

Curis's EPS has surged by 52% YoY and by 10% QoQ

The equity has contracted by 8% from the previous quarter

CRIS's price to sales (P/S) is 40% higher than its last 4 quarters average of 53.8

The revenue has declined by 9% year-on-year

Efficiency

How efficient is Curis business performance

The ROIC has soared by 91% YoY and by 26% from the previous quarter

The company's return on assets has surged by 74% YoY and by 11% QoQ

CRIS's return on equity is up by 35% since the previous quarter

Curis's return on sales has decreased by 19% YoY and by 15% QoQ

Dividends

What is CRIS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time

The company's total assets is 164% higher than its total liabilities

The current ratio has declined by 14% since the previous quarter

CRIS's quick ratio is down by 13% since the previous quarter

CRIS's debt is 95% less than its equity

The debt to equity has soared by 119% YoY

CRIS's debt is down by 34% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.